SABCS Abstracts excluding those that have been embargoed are available for viewinghere.
___________________________________
This is a huge annual event and would seem the ideal time for a presentation from Dana Farber, for Kazia BCBM Trial. ......especially in view of very recent advice from the company that this presentation was imminent (this Calendar year.)
Priscilla Brastanious will be presenting.....Nancy Lin (Dana Farber Breast Cancer boss) will be there and talking also.
However there are hundreds of individual presentations on breast cancer over the 4 days ...despite spending time trying to find the relevant presentation for the Kazia Trial - I have not been able to do so. Unlike SNO, the search option is pretty much ineffective. Our presentation may well be listed, but who has got a couple of hours to find.....and a very tedious couple of hours at that.
Anyway a big like from me, if anybody else has information here.
_______________________________
Just again to day on that 4.8 month OS reported. This is a fantastic result in GBM and a single drug. Another terrific story here, which perfectly confirms what I have said. Market does not understand.
Dozens of new cancer drugs do little to improve survival
Liz Szabo
Kaiser Health News
Overall cancer survival has barely changed over the past decade. The 72 cancer therapies approved from 2002 to 2014 gave patients only 2.1 more months of life than older drugs, according to a study in JAMA Otolaryngology–Head & Neck Surgery.
Recognizing the slow pace of progress, the American Society of Clinical Oncology has set goals for new cancer drugs of extending life or controlling tumors for at least 2.5 months. The bar was set relatively low because “it’s not very often that we come across a transformative treatment,” said Dr. Sham Mailankody, an assistant attending physician and myeloma specialist at Memorial Sloan Kettering.
KZA Price at posting:
$1.57 Sentiment: Buy Disclosure: Held
